Metastatic Clear Cell Renal Cell Carcinoma Clinical Trial
Official title:
A Phase II Trial of High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Metastatic Clear Cell Renal Cell Cancer (mRCC)
In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide antigen presentation and immune stimulation which is expected to act synergistically when immediately followed by the non-specific immune stimulation provided by treatment with HD IL-2 and thereby increase the response rate and complete response for metastatic clear cell renal cell cancer patients. Both HD IL-2 and SABR are FDA approved therapeutic cancer treatment
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01510119 -
Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06059014 -
Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05122546 -
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04904302 -
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
|
Phase 2 | |
| Recruiting |
NCT04510597 -
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
|
Phase 3 | |
| Terminated |
NCT02781506 -
Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06399419 -
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06361810 -
PSMA Therapy and Immunotherapy in Kidney Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06428708 -
[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma
|
Early Phase 1 | |
| Recruiting |
NCT04370509 -
Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery
|
Phase 2 | |
| Recruiting |
NCT05012371 -
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
|
Phase 2 | |
| Terminated |
NCT03334409 -
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT02848768 -
Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma
|
N/A | |
| Recruiting |
NCT05361720 -
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
|
Phase 2 | |
| Terminated |
NCT03260504 -
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
|
Phase 1 | |
| Completed |
NCT02002312 -
Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
|
Phase 2 | |
| Terminated |
NCT01391130 -
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04388852 -
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
|
Phase 1 | |
| Recruiting |
NCT05879471 -
68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06349642 -
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
|